Strongest evidence
The most robust research on Lactobacillus salivarius UCC118 relates to reduced inflammation — 8 studies, all beneficial, with moderate evidence strength. A meta-analysis (n=896) reported a mean reduction in C-reactive protein of -1.93 mg/dL, and an RCT in multiple sclerosis patients found significant decreases in CRP, TNF-α, and IFN-γ. Evidence for improved insulin sensitivity is also moderate (6 studies, all beneficial), though every study used mixed probiotic blends, making the specific contribution of UCC118 unclear. Similarly, reduced prevalence of gestational diabetes mellitus shows moderate support from 4 studies (risk reductions of 29–48% in meta-analyses), but all data come from pregnant women.
Mixed or weaker evidence
Low-strength evidence supports potential benefits for improved glucose metabolism (4 studies, all beneficial), improved exercise performance (3 studies, all beneficial), and reduced infection risk (3 studies, all beneficial). However, these syntheses rely entirely on review articles without original human trials — no statistically significant findings were reported for exercise or infection. Gastrointestinal health (10 studies, all beneficial) and gut health (6 studies, all beneficial) carry very low evidence strength, as every included study is a review or non-human report. No study reached statistical significance for gastrointestinal outcomes. Immune modulation (3 studies, small effects) and immune function (5 studies, small effects) also rest entirely on narrative reviews.
Effective dose patterns
No cross-cutting dose patterns emerged. Across all 12 syntheses, effective doses were not consistently reported — most studies used mixed probiotic formulations at unspecified concentrations, making dose-response conclusions impossible for this specific strain.
Population insights
The clearest population-specific findings come from pregnant women, particularly those with gestational diabetes mellitus (GDM). All evidence for insulin sensitivity and GDM risk reduction originates from this group. Anti-inflammatory effects were observed across broader populations, including multiple sclerosis patients and individuals with obesity or inflammatory bowel disease. No data support specific benefits in men, non-pregnant women, children, or elderly populations.
Notable caveats
Publication bias is flagged in most syntheses — null-result studies are less likely to be published or indexed, potentially inflating the apparent benefit. The majority of evidence comes from reviews or preclinical studies; only one RCT specifically tested UCC118 for inflammation. For outcomes like improved glucose metabolism, only 2 of 4 studies reported statistically significant findings. Across all syntheses, no study reported a specific dose, duration, or formulation tested in humans for UCC118 as a single strain.